Compare DexCom, Inc. (DXCM) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total World Stock Index Fund ETF — how do they compare? DexCom, Inc. trades at $84.46 (market cap $31.81B), while Vanguard Total World Stock Index Fund ETF trades at $159.17 (market cap $101.70B). The key difference: Vanguard Total World Stock Index Fund ETF is far larger — about 3.2× DexCom, Inc.'s market cap, and Vanguard Total World Stock Index Fund ETF is more actively traded (3,514,160 versus 2,861,821). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Total World Stock Index Fund ETF for 53 Days on average.
| DXCM | VT | |
|---|---|---|
Market Cap | $31.81B | $101.70B |
Volume | 2,861,821 | 3,514,160 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $162.39 |
52-Week Low | $54.84 | $134.19 |
Typical Hold Time | 62 Days | 53 Days |
Enterprise Value | $31.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 1.22% amid a bearish technical outlook. The company demonstrates strong fundamental performance with consistent earnings beats, including Q2 2026 EPS of $0.70 exceeding expectations of $0.611. Revenue growth remains robust, climbing from $2.9B in 2022 to $4.7B in 2025, while net income margins improved to 17.93%. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
Wall Street maintains a bullish stance with 81% buy ratings and a $95.07 consensus price target, representing 13% upside potential. Key risks include competitive pressures in CGM markets and reimbursement challenges. The company's strong cash flow generation and expanding market opportunity in diabetes technology support long-term growth prospects despite current technical weakness.
Vanguard Total World Stock ETF (VT) trades at $159.64, down 0.66% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF maintains strong global diversification with over 9,700 holdings across developed and emerging markets. Recent news highlights VT's competitive positioning against peers like Schwab International Equity ETF and iShares MSCI World ETF, with analysts noting its comprehensive exposure and long-term performance advantages.
VT offers investors broad global equity exposure with low costs, though its expense ratio of 0.06% faces pressure from cheaper alternatives. The ETF's performance remains tied to global economic conditions, with risks including trade policy uncertainty and currency fluctuations. Analyst sentiment is generally positive for long-term diversification strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
